John Öhd,
The third quarter in figures
- The loss after tax amounted to TSEK 3 093 (2 908).
- The loss per share amounted to
SEK 0,19 (0,18). - The cash flow from current operations was negative in the amount of TSEK 2 955 (2 760).
The first 9-months in figures
- The loss after tax amounted to TSEK 13 828 (8 964).
- The loss per share amounted to
SEK 0,86 (0,56). - The cash flow from current operations was negative in the amount of TSEK 13 557 (13 532).
Important events during the third quarter
No events to report.
Important events after the end of the period
Modus Therapeutics presents final data from its Phase 1b LPS-provocation study with sevuparin at the annual ISICIP symposium inBarcelona .Modus Therapeutics to present at the 2023American Society of Hematology Meeting and Exposition (ASH): New data on sevuparin and its potential to treat chronic kidney disease anemia and reduce kidney injury.- Modus participated in BIO-
EUROPE . - On
8 November 2023 , the Board of Directors resolved, with the support of the Annual General Meeting's authorization, to carry out a rights issue of approximatelySEK 40,3 million and a set-off issue ofSEK 20,3 million . The Rights Issue is primarily intended to finance general working capital, a clinical phase IIa study in anemia, preparation for the rest of the clinical program, as well as the storage of sevuparin and its distribution to the malaria study.
© Modular Finance, source